Spotlight Innovation Subsidiary Celtic Biotech Iowa to Present Two Posters at 2018 American Association for Cancer Research (AACR) Annual Meeting

URBANDALE, IA, March 28, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company subsidiary Celtic Biotech Iowa, Inc., will present two posters at the American Association for Cancer Research (AACR) Annual Meeting taking place April 14-18, 2018, at the McCormick Place Convention Center in Chicago, IL.

“We look forward to sharing at the AACR Annual Meeting details of the progress we've made advancing Crotoxin through early clinical trials," said Dr. Paul Reid, President of Celtic Biotech Iowa.

Poster presentations:

Title: Innovative design for a phase I trial with intra-patient dose escalation: The Crotoxin study
Date and Time: Monday April 16, 2018 from 8:00 AM - 12:00 PM CDT
Location: Poster Section 42, Exhibit Hall A, McCormick Place South
Abstract Number: CT070, Poster Board Number 23
Presenting Author: Dr. Jacques Medioni, Centre for Early-Phase Trials in Cancer (CEPEC), Hôpital Européen Georges Pompidou, Paris, France, and Paris Descartes University, Paris, France

Title: Continuous i.v. Crotoxin in advanced cancer: Intra-patient dose escalation
Date and Time: Monday April 16, 2018 from 8:00 AM - 12:00 PM CDT
Location: Poster Section 42, Exhibit Hall A, McCormick Place South
Abstract Number: CT071, Poster Board Number 24
Presenting Author: Dr. Marian Gil-Delgado, Medical Oncology Service University Hospital Pitié-Salpêtrière, Paris, France

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) acquires and develops proprietary therapies to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. The Company identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations (CROs), and contract manufacturing organizations (CMOs). At the appropriate stage of research and development the Company will endeavor to pursue product commercialization opportunities including, but not limited to, out-licensing and strategic partnerships with industry leaders. For more information, visit or

About Celtic Biotech Iowa, Inc.

Spotlight Innovation subsidiary Celtic Biotech Iowa, Inc., is developing novel therapeutic products for the treatment of cancer. Derived from specialized receptor binding proteins found in snake venom, these product candidates have the potential to reduce treatment costs, increase survival, and improve quality-of-life for cancer patients.

Forward-Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include, but are not limited to, statements regarding efforts by Spotlight Innovation and Celtic Biotech Iowa to develop and commercialize various therapies, and to achieve stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: uncertainties inherent in clinical trials; the inability to finance the planned development of the therapies; the inability to hire appropriate staff to develop the therapies; unforeseen technical difficulties in developing the therapies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Rene Erickson
Spotlight Innovation Inc.
[email protected]

Primary Logo

Source: Spotlight Innovation Inc.